MedTrace Logo

Efficacy and Safety of Nexpowder™ for Non-variceal, Upper Gastrointestinal Bleeding

NCT06269588 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2024-02-21

No results posted yet for this study

Summary

The purpose of this pilot clinical trial is to confirm the efficacy and safety of Nexpowder™ for hemostasis in pilot cohort of patients with NVUGIB in Singapore

Conditions

  • Gastrointestinal Hemorrhage
  • Hematemesis; With Ulcer
  • Endoscopy

Interventions

DEVICE

Nexpowder

Endoscopic hemostasis

Sponsors & Collaborators

  • Next Biomedical Co., Ltd.

    collaborator INDUSTRY

  • Tan Tock Seng Hospital

    collaborator OTHER

  • National University Hospital, Singapore

    collaborator OTHER

  • Changi General Hospital

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-02-29
Primary Completion
2024-12-31
Completion
2024-12-31

Countries

  • Singapore

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06269588 on ClinicalTrials.gov